TR200101262T2 - Uzun süreli salınımlı ranolazin formülasyonları - Google Patents

Uzun süreli salınımlı ranolazin formülasyonları

Info

Publication number
TR200101262T2
TR200101262T2 TR2001/01262T TR200101262T TR200101262T2 TR 200101262 T2 TR200101262 T2 TR 200101262T2 TR 2001/01262 T TR2001/01262 T TR 2001/01262T TR 200101262 T TR200101262 T TR 200101262T TR 200101262 T2 TR200101262 T2 TR 200101262T2
Authority
TR
Turkey
Prior art keywords
ranolazine
prolonged
aqueous medium
release ranolazine
ranolazine formulations
Prior art date
Application number
TR2001/01262T
Other languages
English (en)
Turkish (tr)
Inventor
A. Wolff Andrew
Baker Fiona
Langridge John
Original Assignee
Cv Therapeutics, Inc.
Syntex (U.S.A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200101262(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics, Inc., Syntex (U.S.A.) Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200101262T2 publication Critical patent/TR200101262T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
TR2001/01262T 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları TR200101262T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (1)

Publication Number Publication Date
TR200101262T2 true TR200101262T2 (tr) 2001-12-21

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/01262T TR200101262T2 (tr) 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları
TR2001/01261T TR200101261T2 (tr) 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/01261T TR200101261T2 (tr) 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları.

Country Status (33)

Country Link
US (14) US6303607B1 (forum.php)
EP (3) EP1527779A1 (forum.php)
JP (2) JP3745621B2 (forum.php)
KR (1) KR100475759B1 (forum.php)
CN (2) CN1193757C (forum.php)
AR (3) AR022085A1 (forum.php)
AT (2) ATE217794T1 (forum.php)
AU (4) AU744071B2 (forum.php)
BR (2) BR9913553A (forum.php)
CA (2) CA2342390C (forum.php)
CY (1) CY2008020I2 (forum.php)
CZ (2) CZ301375B6 (forum.php)
DE (3) DE69901570T2 (forum.php)
DK (2) DK1096937T3 (forum.php)
ES (2) ES2177346T3 (forum.php)
FR (1) FR09C0001I2 (forum.php)
GE (1) GEP20053420B (forum.php)
HK (1) HK1044284B (forum.php)
HU (2) HUP0104088A3 (forum.php)
IL (6) IL141892A0 (forum.php)
LU (1) LU91504I2 (forum.php)
MX (2) MXPA01002598A (forum.php)
NL (1) NL300371I2 (forum.php)
NO (4) NO319434B1 (forum.php)
NZ (2) NZ510384A (forum.php)
PL (3) PL196668B1 (forum.php)
PT (2) PT1109558E (forum.php)
RU (2) RU2214233C2 (forum.php)
SI (2) SI1109558T1 (forum.php)
TR (2) TR200101262T2 (forum.php)
TW (1) TWI241911B (forum.php)
UA (2) UA67793C2 (forum.php)
WO (2) WO2000013687A2 (forum.php)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
KR20020075801A (ko) * 2000-02-18 2002-10-05 씨브이 쎄러퓨틱스, 인코포레이티드 울혈성 심부전 치료의 부분적 지방산 산화 방지제
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
WO2003099281A2 (en) * 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
US20060177502A1 (en) * 2005-01-06 2006-08-10 Srikonda Sastry Sustained release pharmaceutical formulations
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CA2616845A1 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
US20090091253A1 (en) * 2006-03-17 2009-04-09 Konica Minolta Holdings, Inc. Organic electroluminescent element, display device and lighting device
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
EP2117508A1 (en) 2007-02-13 2009-11-18 CV Therapeutics Inc. Intravenous solutions comprising ranolazine
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
CN101977605A (zh) * 2008-02-06 2011-02-16 吉利德科学股份有限公司 雷诺嗪治疗疼痛的用途
EP2429526A1 (en) * 2009-05-14 2012-03-21 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (forum.php) 2011-07-01 2018-04-28
HK1200114A1 (en) 2011-09-21 2015-07-31 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
DE69028457T2 (de) * 1989-06-23 1997-02-20 Syntex (U.S.A.) Inc., Palo Alto, Calif. Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
DE122008000065I1 (de) 2009-04-09
NO2009005I1 (no) 2009-03-16
CZ301375B6 (cs) 2010-02-03
EP1096937B1 (en) 2004-12-29
US20060217397A1 (en) 2006-09-28
AU2008207703A1 (en) 2008-09-25
NO320986B1 (no) 2006-02-20
HUP0103844A3 (en) 2002-11-28
FR09C0001I2 (forum.php) 2009-12-18
ES2234302T3 (es) 2005-06-16
JP2002524416A (ja) 2002-08-06
US20020004506A1 (en) 2002-01-10
WO2000013687A2 (en) 2000-03-16
TR200101261T2 (tr) 2002-05-21
US20050153982A1 (en) 2005-07-14
LU91504I2 (fr) 2009-02-03
JP2006096757A (ja) 2006-04-13
PL202207B1 (pl) 2009-06-30
CY2008020I1 (el) 2010-07-28
FR09C0001I1 (forum.php) 2009-02-27
NL300371I1 (nl) 2009-02-02
US6562826B1 (en) 2003-05-13
BR9913626A (pt) 2001-12-04
UA67793C2 (uk) 2004-07-15
NO20011191D0 (no) 2001-03-08
HK1044284B (zh) 2005-07-15
NL300371I2 (nl) 2009-10-01
CN1193757C (zh) 2005-03-23
NZ510386A (en) 2003-08-29
PT1109558E (pt) 2002-10-31
DE69901570D1 (de) 2002-06-27
AR052921A1 (es) 2007-04-11
ES2177346T3 (es) 2002-12-01
IL141893A0 (en) 2002-03-10
WO2000013686A3 (en) 2000-07-06
US20040029890A1 (en) 2004-02-12
ATE285774T1 (de) 2005-01-15
AR053440A2 (es) 2007-05-09
US6617328B2 (en) 2003-09-09
NO20011192L (no) 2001-04-30
NO20011192D0 (no) 2001-03-08
RU2207856C2 (ru) 2003-07-10
NO2009005I2 (forum.php) 2010-06-28
WO2000013687A3 (en) 2000-06-29
US6864258B2 (en) 2005-03-08
EP1096937B9 (en) 2007-02-28
US20060147521A1 (en) 2006-07-06
CZ2001880A3 (cs) 2001-08-15
ATE217794T1 (de) 2002-06-15
AU744071B2 (en) 2002-02-14
AU6036499A (en) 2000-03-27
HUP0103844A2 (hu) 2002-04-29
SI1109558T1 (en) 2002-10-31
CA2343376A1 (en) 2000-03-16
US6620814B2 (en) 2003-09-16
US20030166659A1 (en) 2003-09-04
EP1527779A1 (en) 2005-05-04
JP3745621B2 (ja) 2006-02-15
KR100475759B1 (ko) 2005-03-10
KR20010089874A (ko) 2001-10-12
CZ2001879A3 (cs) 2001-08-15
EP1109558A2 (en) 2001-06-27
CA2342390C (en) 2006-08-29
IL141892A (en) 2006-08-20
NZ510384A (en) 2002-10-25
UA75027C2 (uk) 2006-03-15
CN1321088A (zh) 2001-11-07
HUP0104088A2 (hu) 2002-05-29
US20050059667A1 (en) 2005-03-17
IL141893A (en) 2008-08-07
CY2008020I2 (el) 2010-07-28
DE69922964T2 (de) 2005-12-08
HK1044284A1 (en) 2002-10-18
PT1096937E (pt) 2005-04-29
NO20054324L (no) 2001-04-30
DK1109558T3 (da) 2002-08-26
MXPA01002599A (es) 2005-02-17
CZ301341B6 (cs) 2010-01-20
CA2342390A1 (en) 2000-03-16
US20040097514A1 (en) 2004-05-20
EP1096937A2 (en) 2001-05-09
MXPA01002598A (es) 2002-04-08
SI1096937T1 (en) 2005-04-30
IL175371A0 (en) 2006-09-05
NO319434B1 (no) 2005-08-15
AU760435B2 (en) 2003-05-15
TWI241911B (en) 2005-10-21
CN1211086C (zh) 2005-07-20
US6303607B1 (en) 2001-10-16
DE69922964D1 (de) 2005-02-03
DE69901570T2 (de) 2003-01-09
LU91504I9 (forum.php) 2019-01-02
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
PL196668B1 (pl) 2008-01-31
US20020090396A1 (en) 2002-07-11
HU224215B1 (hu) 2005-06-28
IL141892A0 (en) 2002-03-10
US20030099705A1 (en) 2003-05-29
IL180864A0 (en) 2007-07-04
PL196263B1 (pl) 2007-12-31
US6525057B2 (en) 2003-02-25
AR022085A1 (es) 2002-09-04
AU6142599A (en) 2000-03-27
CN1354665A (zh) 2002-06-19
EP1109558B1 (en) 2002-05-22
AU2008207707A1 (en) 2008-09-25
BR9913553A (pt) 2001-10-23
CA2343376C (en) 2007-01-09
US6503911B2 (en) 2003-01-07
GEP20053420B (en) 2005-01-25
DK1096937T3 (da) 2005-05-09
PL348249A1 (en) 2002-05-20
RU2214233C2 (ru) 2003-10-20
US6369062B1 (en) 2002-04-09
HK1040060A1 (en) 2002-05-24
HUP0104088A3 (en) 2002-12-28
US6852724B2 (en) 2005-02-08
NO20011191L (no) 2001-04-30
US20030100566A1 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
TR200101262T2 (tr) Uzun süreli salınımlı ranolazin formülasyonları
WO2001066093A3 (en) Sustained release ranolazine formulations
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
NO20083842L (no) Anvendelse av opploselig lymfotoksin-beta-reseptor for fremstilling av medikamenter
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
ATE83375T1 (de) Pharmazeutische zusammensetzungen.
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
PL346764A1 (en) New oral formulation for 5-ht4
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
AU5938398A (en) Pour-on formulations containing polymeric material, glycols and glycerides
BR0115518A (pt) Kit de repinotan
YU28002A (sh) Farmaceutska kompozicija koja sadrži ciklesonid za primenu na sluzokoži
TR200100896T2 (tr) İkameli propanol türevleri, imalat yöntemleri, bileşimleri içeren ilaçlar, kullanımları
AU3455093A (en) New adenosine derivatives, preparation methods and pharmaceutical compositions containing them
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
SE0001916D0 (sv) Novel formulation
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
ATE71535T1 (de) Pharmazeutische zubereitungen.
EP0791350A3 (de) Mittel zur dauerhaften Verformung von menschlichen Haaren
SE9604752D0 (sv) Formulation and use
MY106672A (en) Dichloroaniline compound.
PT1603559E (pt) Composição farmacêutica para acidificação intracelular com cis-urocânico
AU2002221772A1 (en) Derivatives of the human macrophage-migration inhibition factor (mif) and use thereof in pharmaceutical preparations in screening methods or the identification of analogues, agonists and antagonists